⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of NovoPedics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
NovoPedics, Inc.
↗Monmouth Junction, United States
NovoPedics is a privately held New Jersey medical-device startup developing MeniscoFix™, a bioresorbable, polymer fiber-reinforced scaffold intended for partial or total meniscus replacement. The device is designed to replicate key architectural and biomechanical characteristics of the native meniscus, provide immediate load sharing after implantation, attach to soft tissue and bone, and gradually resorb while supporting formation of functional neo-meniscus tissue. ([novopedics.com](https://www.novopedics.com/about.php))
The company originated from Rutgers University and Robert Wood Johnson Medical School orthopedic research. Its technology portfolio has been exclusively licensed from Rutgers, and development has been supported by Foundation Venture Capital Group, U.S. Department of Defense awards, NIH/NIAMS SBIR funding, and New Jersey state innovation programs. As of February 2026, public Rutgers materials described the company as still in preclinical development, with an FDA Investigational Device Exemption submission for a first-in-human study planned for 2026. ([research.rutgers.edu](https://research.rutgers.edu/sites/default/files/2026-02/2026-ris-acceptedposters.pdf?utm_source=openai))
CLASSIFICATION
Company Type:MedTech
Therapeutic Areas:-
Industry:Medical Devices
Sub-Industry:Orthopedic regenerative medicine and bioresorbable meniscal implants
SIZE & FINANCIALS
Employees:1-50
Revenue:Less than $0.5M, according to a public small-business profile; no audited revenue disclosure located. ([inknowvation.com](https://www.inknowvation.com/node/199488?utm_source=openai))
Founded:2013
Ownership:private
Status:operating
FUNDING
Stage:Seed
Total Raised:$7.2M+ in publicly documented venture commitments, grants, and awards; not all amounts necessarily represent direct company proceeds
Investors:Foundation Venture Capital Group — committed up to $500,000 in April 2013 to advance the implantable meniscus program. ([novopedics.com](https://www.novopedics.com/cmsAdmin/uploads/news-fvcg-investment.pdf))
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical; MeniscoFix is a medical device rather than a drug. An IDE submission for a first-in-human clinical trial was described as planned for 2026. ([research.rutgers.edu](https://research.rutgers.edu/sites/default/files/2026-02/2026-ris-acceptedposters.pdf?utm_source=openai))
Modalities:Bioresorbable polymer scaffold, Fiber-reinforced biomaterial implant, Collagen and hyaluronic-acid-infused scaffold, 3D-printed polymeric scaffold, Tissue-engineered fibrocartilage replacement, Personalized/anatomically matched implant fabrication
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Rutgers University and Robert Wood Johnson Medical School — originating research institution and exclusive licensor of the MeniscoFix intellectual property. ([research.rutgers.edu](https://research.rutgers.edu/sites/default/files/2026-02/2026-ris-acceptedposters.pdf?utm_source=openai)), U.S. Department of Defense / U.S. Army Medical Research Acquisition Activity — Rutgers-led $4.42M award/subaward supporting preclinical MeniscoFix development, manufacturing, safety, and efficacy work. ([novopedics.com](https://www.novopedics.com/cmsAdmin/uploads/novopedics-receives-subaward-through-rutgers-university-final.pdf)), NIH National Institute of Arthritis and Musculoskeletal and Skin Diseases — Phase I SBIR award of $275,546 in 2022 and a $2M Phase II SBIR award announced in July 2025. ([dnb.inknowvation.com](https://www.dnb.inknowvation.com/sbir/awards/nih-2022-pre-clinical-optimization-meniscofix-novel-total-meniscus-replacement-implant?utm_source=openai)), Foundation Venture Capital Group — early venture backer with a commitment of up to $500,000. ([novopedics.com](https://www.novopedics.com/cmsAdmin/uploads/news-fvcg-investment.pdf)), New Jersey Commission on Science, Innovation and Technology / NJEDA — state innovation and SBIR-matching support identified in public state records. ([njcsit.gov](https://www.njcsit.gov/wp-content/uploads/2025/06/FINAL-051925-Awardee-Profiles_2024-CSIT-Report1.pdf?utm_source=openai))
COMPETITION
Position:Emerging
Competitors:Active Implants — NUsurface meniscus implant, a synthetic meniscal replacement alternative., Orteq — Actifit meniscal scaffold, a partial-meniscus tissue-regeneration alternative., Stryker and related collagen-meniscus implant technologies — collagen-based partial meniscal replacement alternatives., Meniscal allograft transplantation providers — established surgical alternative using cadaveric tissue., Arthrex, Stryker, Zimmer Biomet, and other orthopedic-device companies — broader competitors for surgeon attention, knee-repair procedures, and future meniscal-replacement commercialization., Total knee arthroplasty and osteotomy procedures — downstream procedural alternatives for patients with advanced post-meniscectomy degeneration.
LEADERSHIP
Key Executives:
Charles J. Gatt, Jr., MD - Founder and CEO
Michael G. Dunn, PhD - Founder, Secretary and Treasurer
Kevin Weadock, PhD - Chief Operating Officer
Cori Lichter, MS - Manager, Product Development
Claudia Campbell-Matland, PMP - Project Manager and Acting Director of Quality
Scientific Founders:Charles J. Gatt, Jr., MD — orthopedic surgeon and co-founder. ([novopedics.com](https://www.novopedics.com/cmsAdmin/uploads/news-fvcg-investment.pdf)), Michael G. Dunn, PhD — orthopedic tissue-engineering researcher and co-founder. ([novopedics.com](https://www.novopedics.com/cmsAdmin/uploads/news-fvcg-investment.pdf)), Eric A. Balint, PhD/MD — Rutgers scientific co-inventor associated with the foundational MeniscoFix patent family and 2021 Edison Patent Award. ([newswise.com](https://www.newswise.com/articles/rutgers-inventors-dunn-balint-and-gatt-receive-2021-edison-patent-award-in-biotechnology-category?utm_source=openai))
Board Members:Charles J. Gatt, Jr., MD — Founder and CEO. ([novopedics.com](https://www.novopedics.com/about.php)), James M. Golubieski — Representative of Foundation Venture Capital Group. ([novopedics.com](https://www.novopedics.com/about.php)), Vince Smeraglia, Esq. — Rutgers observer. ([novopedics.com](https://www.novopedics.com/about.php))
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with NovoPedics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.